Peptide Research: AOD9604 – Studies, Research Use, and Scientific Background

What is AOD9604?

AOD9604 is a synthetic peptide fragment of human growth hormone (GH) consisting of amino acids 176–191. It has been investigated in laboratory research for its potential to modulate fat metabolism, support lipolysis, and regulate adipose tissue function in preclinical models, without affecting growth or insulin sensitivity.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

• Fat Metabolism and Lipolysis: A study published in Obesity Research (2004) demonstrated that AOD9604 enhanced fat breakdown and reduced body fat in animal models without influencing blood glucose or growth.
  Heath et al., 2004
• Safety and Metabolic Effects: Laboratory and early clinical studies have investigated the safety, metabolism, and pharmacokinetics of AOD9604, supporting its profile as a research tool for adipose regulation.
  Ng FM et al., 2008

Laboratory Research Applications

• Research on adipose tissue regulation and metabolism
• Preclinical models of obesity and fat loss
• Studies of lipolysis and lipid oxidation pathways
• Investigation of peptide hormone fragments in metabolic research

Mechanism of Action (in Research Context)

AOD9604 is believed to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) in adipose tissue by mimicking the actions of growth hormone’s 176–191 fragment. In preclinical studies, this effect is achieved without altering IGF-1 levels or promoting growth.

Reference Dosing Schedules from Published Studies

The following dosing protocols have been reported in published laboratory and preclinical studies of AOD9604:

• Common Dose Range (animal studies): 0.25–5 mg/kg, administered subcutaneously
• Duration: Typically 14–28 days, depending on experimental protocol